OBJECTIVE: Melanin-concentrating hormone (MCH) is a hypothalamic orexigenic neuropeptide that regulates energy balance. However, the distribution of MCH and its receptor MCHR1 in tissues other than brain suggested additional, as yet unappreciated, roles for this neuropeptide. Based on previous paradigms and the presence of MCH in the intestine as well as in immune cells, its potential role in gut innate immune responses was examined. METHODS: In human intestinal xenografts grown in mice, changes in the expression of MCH and its receptors following treatment with Clostridium difficile toxin A, the causative agent of antibiotic-associated diarrhoea in hospitalised patients, were examined. In colonocytes, the effect of C difficile toxin A treatment on MCHR1 expression, and of MCH on interleukin 8 (IL8) expression was examined. MCH-deficient mice and immunoneutralisation approaches were used to examine the role of MCH in the pathogenesis of C difficile toxin A-mediated acute enteritis. RESULTS: Upregulation of MCH and MCHR1 expression was found in the human intestinal xenograft model, and of MCHR1 in colonocytes following exposure to toxin A. Treatment of colonocytes with MCH resulted in IL8 transcriptional upregulation, implying a link between MCH and inflammatory pathways. In further support of this view, MCH-deficient mice developed attenuated toxin A-mediated intestinal inflammation and secretion, as did wild-type mice treated with an antibody against MCH or MCHR1. CONCLUSION: These findings signify MCH as a mediator of C difficile-associated enteritis and possibly of additional gut pathogens. MCH may mediate its proinflammatory effects at least in part by acting on epithelial cells in the intestine.
OBJECTIVE:Melanin-concentrating hormone (MCH) is a hypothalamic orexigenic neuropeptide that regulates energy balance. However, the distribution of MCH and its receptor MCHR1 in tissues other than brain suggested additional, as yet unappreciated, roles for this neuropeptide. Based on previous paradigms and the presence of MCH in the intestine as well as in immune cells, its potential role in gut innate immune responses was examined. METHODS: In human intestinal xenografts grown in mice, changes in the expression of MCH and its receptors following treatment with Clostridium difficiletoxin A, the causative agent of antibiotic-associated diarrhoea in hospitalised patients, were examined. In colonocytes, the effect of C difficile toxin A treatment on MCHR1 expression, and of MCH on interleukin 8 (IL8) expression was examined. MCH-deficientmice and immunoneutralisation approaches were used to examine the role of MCH in the pathogenesis of C difficile toxin A-mediated acute enteritis. RESULTS: Upregulation of MCH and MCHR1 expression was found in the human intestinal xenograft model, and of MCHR1 in colonocytes following exposure to toxin A. Treatment of colonocytes with MCH resulted in IL8 transcriptional upregulation, implying a link between MCH and inflammatory pathways. In further support of this view, MCH-deficientmice developed attenuated toxin A-mediated intestinal inflammation and secretion, as did wild-type mice treated with an antibody against MCH or MCHR1. CONCLUSION: These findings signify MCH as a mediator of C difficile-associated enteritis and possibly of additional gut pathogens. MCH may mediate its proinflammatory effects at least in part by acting on epithelial cells in the intestine.
Authors: C R Mantyh; T N Pappas; J A Lapp; M K Washington; L M Neville; J R Ghilardi; S D Rogers; P W Mantyh; S R Vigna Journal: Gastroenterology Date: 1996-11 Impact factor: 22.682
Authors: I Castagliuolo; A C Keates; B Qiu; C P Kelly; S Nikulasson; S E Leeman; C Pothoulakis Journal: Proc Natl Acad Sci U S A Date: 1997-04-29 Impact factor: 11.205
Authors: C P Kelly; S Becker; J K Linevsky; M A Joshi; J C O'Keane; B F Dickey; J T LaMont; C Pothoulakis Journal: J Clin Invest Date: 1994-03 Impact factor: 14.808
Authors: Dimitrios C Ziogas; Apostolos K A Karagiannis; Brenda M Geiger; Beatriz Gras-Miralles; Robert Najarian; Ofer Reizes; Leo R Fitzpatrick; Efi Kokkotou Journal: Peptides Date: 2014-02-18 Impact factor: 3.750
Authors: Dimitrios C Ziogas; Beatriz Gras-Miralles; Sarah Mustafa; Brenda M Geiger; Robert M Najarian; Jutta M Nagel; Sarah N Flier; Yury Popov; Yu-Hua Tseng; Efi Kokkotou Journal: Am J Physiol Gastrointest Liver Physiol Date: 2013-03-28 Impact factor: 4.052
Authors: Kevin M D'Auria; Glynis L Kolling; Gina M Donato; Cirle A Warren; Mary C Gray; Erik L Hewlett; Jason A Papin Journal: Infect Immun Date: 2013-07-29 Impact factor: 3.441
Authors: Apostolos K A Karagiannis; Dimitrios C Ziogas; Beatriz Gras-Miralles; Brenda M Geiger; Jutta Nagel; Estela Trebicka; Robert Najarian; Bobby J Cherayil; Efi Kokkotou Journal: Infect Immun Date: 2012-10-31 Impact factor: 3.441
Authors: Jutta M Nagel; Brenda M Geiger; Apostolos K A Karagiannis; Beatriz Gras-Miralles; David Horst; Robert M Najarian; Dimitrios C Ziogas; Xinhua Chen; Efi Kokkotou Journal: PLoS One Date: 2012-07-27 Impact factor: 3.240